Sexually transmitted diseases (STDs) are cofactors for human immunodeficiency virus (HIV) transmission, but the specific role of herpes simplex virus type 2 (HSV-2) is unclear. This study aimed to examine the in vivo relationships between HSV-2 and HIV-1 in 300 women in Bangui, Central African Republic. Sera were tested for syphilis, HIV-1, HSV-2 antibody, and levels of vitamins A and E. Genital specimens were tested for other STDs. HSV-2 DNA and HIV-1 RNA were quantified in cervicovaginal lavage. The prevalences of HSV-2 antibody (91% vs. 78%, ), HSV-2 shedding (43% vs. 22%, ), and levels P p .02 P p .003 of HSV-2 DNA ( ) were all significantly higher among HIV-1-seropositive than among P p .01 HIV-1-seronegative women. There was a significant correlation between genital HIV-1 RNA and HSV-2 DNA levels ( ) among the 23 women who were shedding HSV-2 DNA. If P p .02 confirmed, such associations highlight the urgent need for HSV-2 control measures in populations at high risk of both infections.
Interactions between Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Type 1 Infection in African Women:
Opportunities for Intervention simplex virus type 2 (HSV-2), a major cause of genital ulcer disease (GUD), is highly prevalent in human populations worldwide [4] . The high prevalence of infection, its associated morbidity, and the frequent recurrence of clinical episodes render this disease of great concern to patients and health care providers [5] . Increased genital shedding of HIV reported in men with genital ulcers caused by HSV-2 [6] has further emphasized the importance of this infection. Recent findings clearly indicate that seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes [7] .
In sub-Saharan Africa, studies of HSV-2 have been scarce, owing to the lack of available laboratory tests and facilities. However, high seroprevalence rates in young adults (60%-80%) have been recorded in population-based studies [8] [9] [10] . Recent evidence suggests that an increasing proportion of genital ulcers may be attributed to HSV-2 in many parts of Africa [11] [12] [13] . In fact, HSV-2 infection and recurrences would be expected to increase in frequency and severity in areas with high HIV prevalence, because of immunosuppression [14] .
The present study aimed to measure the HSV-2 seroprevalence and the prevalence of HSV-2 shedding in African women, with or without genital symptoms, living in an area with high HIV-1 prevalence. We sought to investigate the relationship between HSV-2 and HIV-1 infection by comparing the prevalence and quantity of HSV-2 genital shedding in HIV-1-positive and HIV-negative women, as well as the association between HIV-1 and HSV-2 genital shedding among dually infected women.
Subjects and Methods
Three hundred consecutive and consenting women attending the Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA in Bangui, the capital city of the Central African Republic, were enrolled in the study. The center offers multipurpose reproductive health services, including provision of STD services, and operates the main voluntary HIV testing and counseling center in Bangui. Reasons for attendance, sociodemographic and behavioral data, and obstetric and STD histories were elicited in a structured interview. Women underwent general, genital, and pelvic examination, during which serum, vaginal, and cervical samples were collected. Clinical immunosuppression was assessed by using the World Health Organization (WHO) Bangui clinical case definition for AIDS in Africa [15] . A 7-day follow-up appointment was arranged for all women, and appropriate treatment was provided free of charge for any treatable STD syndrome or genital pathogen diagnosed.
Samples Taken and Laboratory Methods
Serology. A venous blood specimen was collected for serological testing and biochemistry. Diagnosis of serological syphilis was done by using the rapid plasma reagin test (VD-25; Murex Diagnostics, Dartford, UK); any positive result was confirmed by the Treponema pallidum hemagglutination assay (Fujirebio, Tokyo). HIV serology was performed according to the WHO testing strategy, using 2 different ELISAs (Genelavia-Mixt HIV-1/HIV-2; Sanofi-Diagnostics Pasteur, Marnes-la-Coquette, France, and Wellcozyme HIV; Murex Diagnostics Ltd, Dartford, UK); discordant results were analyzed by Western blot (New-LAV Blot I; Sanofi-Diagnostics Pasteur). Reactive samples by both ELISAs or those confirmed by Western blot were considered to be HIV-1 seropositive. Serum antibodies to HSV-1 and HSV-2 were measured with a competitive type-specific ELISA with a high sensitivity (93%) and specificity (91%) in comparison with Western blot (the gold standard test for HSV-2 antibodies) on African and UK sera [16] .
Vitamins A and E. The serum concentrations of vitamin A and vitamin E were determined by high-performance liquid chromatography, with the UV reading at 325 nm [17] . The micronutrient levels were compared with international reference values [18] , with vitamin A deficiency defined as levels !30 mg/dL and vitamin E deficiency defined as levels !500 mg/dL. Vitamins A and E are micronutrients with antioxidant/anti-inflammatory properties, and deficiency of these vitamins has been associated with HIV-1 disease progression [19] .
Vaginal and cervical infections. Standard tests were carried out for the following: bacterial vaginosis (BV), by applying Nugent's scoring method of a Gram-stained vaginal smear; Trichomonas vaginalis, by direct microscopy of a wet mount of vaginal secretions; Candida albicans, by culture of a vaginal swab on Sabouraud medium; Neisseria gonorrhoeae, by cervical culture onto a modified Thayer-Martin agar plate; and Chlamydia trachomatis, by an EIA of an endocervical swab, using the Syva Microtrak assay (Syva Co., Palo Alto, CA).
Cervicovaginal lavages. Cervicovaginal secretions (CVSs) were collected by a standardized, nontraumatic 60-s vaginal washing with 3 mL of PBS. The cellular and cell-free fractions were separated by centrifugation and were kept frozen at Ϫ30ЊC until processing. To avoid the possible misclassification of shedding findings that could result from the presence of seminal plasma in the vagina, CVS samples were further evaluated for semen traces. Prostatespecific antigen (PSA) was detected in the supernatant of CVSs by immunoenzymatic tests (PSA IMX System; Abbott Laboratories, Abbott Park, IL). PSA-positive CVSs were excluded from further analyses.
HIV-1 RNA in plasma and in CVSs. HIV-1 RNA levels in plasma and in the acellular fraction of CVSs were measured by using a commercial hypersensitive assay (Amplicor HIV Monitor Test 1.5; Roche Diagnostics Systems, Branchburg, NJ), with a detection threshold of 20 HIV RNA copies/mL and an upper limit of quantitation of 750,000 copies/mL. This polymerase chain reaction (PCR) analysis has a sensitivity of 98.5% and a specificity of 100% for the detection of HIV-1 RNA subtype A [20] , which is the predominant clade in Central Africa.
Statistical Analysis
Data were double-entered and validated by using the Epi-Info 6.0 statistical package (Centers for Disease Control and Prevention, Atlanta). Analyses were carried out by using Stata 6 (Stata Corp., College Station, TX). Virus loads below the detection threshold of 20 copies/mL for both HIV RNA and HSV-2 PCR EIA were included in analyses with a value of 10 copies/mL. Geometric means of virus loads were compared by using a t test on the log values, and correlations between virus loads were assessed by using Spear- man's rank correlation coefficient. Comparisons of 2 proportions were carried out by using the x 2 statistic or Fisher's exact test, where appropriate. Linear regression was used to adjust the log virus load associations for potential confounders. Analyses of HIV-1 and HSV-2 shedding were conducted in the subgroup of women who did not show semen traces in their CVSs, so as to attribute the findings entirely to shedding of the viruses under study.
Results

Population characteristics and STD prevalence.
A total of 300 women were eligible for enrollment, and none refused. The mean age of the study population was 27 years (range, 15-48 years). Median age at time of first sexual intercourse was 16 years, with a median of 2 reported lifetime partners (range, 1-8). The majority of women were married, either in monogamous (47%) or polygamous (13%) marriages. Most women (62%) had reached secondary education level; 40% were employed, and 39% were housewives. None of the participants was taking any antiretroviral drugs.
Women attended the clinic for various reasons, including specific STD services (12%), antenatal care (15%), and family planning services (15%). However, the main category included women attending for "general gynecological problems" (58%). Overall, 262 women (87%) reported a current vaginal discharge, and 37 (12%) reported current genital ulcers, although only 57 (19%) and 10 (3%) were found to have a genital discharge or genital ulcer on clinical examination, respectively (table 1).
The prevalence of the various STD pathogens and STD syndromes is shown in table 1. Nearly 80% of women had an endogenous vaginal infection (C. albicans and/or BV), but only 4 women (1%) had T. vaginalis infection, and 12 (4%) had a cervical infection (N. gonorrhoeae and/or C. trachomatis). Overall, 79 women (26%) were HIV-1 infected , 24 (8%) had evidence of active syphilis, 297 (99%) had antibodies to HSV-1, and 247 (82%) had antibodies to HSV-2. The prevalences of these pathogens and syndromes changed little with regard to PSA status of the CVSs (table 1) . Traces of semen were detected in the CVSs of 61 women (20%), and these subjects were excluded from further analyses involving results obtained on CVS samples. HIV-1-seropositive women were significantly more likely to be HSV-2 seropositive than were HIV-1-seronegative women (91% vs. 78%, ; table 2). Of the 10 women with a clin-P p .02 ically defined ulcer, all were HSV-2 seropositive and 4 were coinfected with HIV. There were no significant differences between HIV-1-seropositive and -seronegative women in terms of other STDs, BV, contraceptive use, or pregnancy status.
The mean serum concentrations of vitamin A and vitamin E were 52 and 995 mg/dL, respectively, and few women were considered to be deficient in either micronutrient: 4% for vitamin A and 1% for vitamin E, respectively. There was a statistically significant difference in the levels of vitamin A between HIV-1-seropositive and HIV-negative individuals ( ), P ! .001 but there was no significant difference in vitamin E levels ( ; 1-seropositive women without semen traces in their CVSs, the geometric mean of HIV-1 RNA plasma load was 3.24 (95% confidence interval [CI], 2.8-3.6) log copies/mL, and the geometric mean of HIV-1 RNA genital tract load was 2.39 (95% CI, 2.1-2.7) log copies/mL. A positive association was observed between HIV-1 RNA levels in the plasma and genital tract, which was of borderline statistical significance (Spearman's rank correlation coefficient ; ; figure 1). HIV-1 RNA was detected in the r p .24 P p .07 CVSs of 31 (76%) of 41 women with detectable HIV-1 RNA in plasma, compared with 9 (53%) of 17 women without detectable plasma HIV-1 RNA (Fisher's exact test, ). P p .12 There were no significant differences between the women with detectable HIV-1 RNA in their CVSs and the others in terms of STD and BV prevalences, vitamin A levels, contraception use, or pregnancy status (data not shown).
HSV-2 genital shedding. Only HSV-2 DNA was detected in the CVSs. Among the 194 HSV-2-seropositive women without semen traces in their CVSs, those also infected with HIV-1 were about twice as likely to be shedding HSV-2 as were HIV-1-negative women (23/ ). There was some evidence that P p .07 the 30 women without HSV-2 DNA were at higher risk of HIV shedding, due to the presence of other STDs. Although they were less likely to have a genital ulcer than were those with HSV-2 DNA (0/30 vs. 3/23, respectively; ), they were P p .08 more likely to have a cervical infection with N. gonorrhoeae and/or C. trachomatis (3/30 vs. 0/23, respectively; ) or P p .25 to have BV (19/30 (63%) vs. 11/23 (48%), respectively; P p ), but none of these differences reached statistical signifi-.26 cance. Levels of vitamin A were similar in both groups (geometric mean, 0.43 mg/dL among women without HSV-2 DNA vs. 0.45 mg/dL among women with HSV-2 DNA;
). P p .80 Despite the overall lack of association between genital shedding of HIV-1 and HSV-2, a significant correlation was observed between genital HIV-1 RNA and genital HSV-2 DNA 
Discussion
The high HSV-2 seroprevalence found in this study is consistent with prevalences recorded in general populations of Africa [8] [9] [10] . Recent studies of patients attending STD services with a complaint of GUD have recorded high rates of HSV-2 isolation (20%-30%) and an association with HIV-1 infection in African settings [11, 12] . In a community-based trial of mass STD treatment in the Rakai district, Uganda, 43% of subjects with genital ulcers were identified with genital herpes by PCR analysis [13] . In contrast, there have been very few studies of genital shedding of HSV-2 among non-GUD patients, particularly among women outside industrialized countries. Our study is the first in sub-Saharan Africa to show both an increased prevalence and an increased quantity of genital HSV-2 shedding among HIV-1-infected women and to show a correlation between the quantities of HIV-1 RNA and HSV-2 DNA in genital secretions among HSV-2 shedders.
Two possibly coexisting mechanisms could explain such findings. First, an increased shedding of both viruses could be observed because of immunosuppression associated with HIV-1 disease, or it could occur under the influence of other systemic or local cofactors of HIV-1 genital shedding. Second, HSV-2 may be an independent cofactor of HIV-1 shedding, and activation of HSV-2 shedding may be accompanied by increased HIV-1 shedding.
In support of the first mechanism, whereby HIV-1 enhances HSV-2 shedding, although anecdotal evidence supports the notion that clinical expression of HSV-2 infection is increased in the presence of advanced HIV-1 disease, there have been surprisingly few studies to examine the impact of HIV infection on the natural history of HSV infection [5] . One previous study demonstrated increased shedding of HSV-2, associated with declining CD4 T cell counts, among HIV-1-seropositive women in New York City [25] . However, in a study of HIV-1-seropositive female sex workers in Mombasa, Kenya, only women with very low CD4 T cell counts (!200/mL) showed increased HSV-2 DNA positivity in cervical swabs [26] . We do not have data on CD4 T cell counts in our study population, but the women attending this outpatient clinic did not show evidence of clinical immunosuppression, as assessed by the WHO Bangui clinical case definition for AIDS in Africa [15] . Furthermore, micronutrient levels in this population were essentially within normal ranges, according to reference values, which suggests that most of these women were not at an advanced stage of HIV infection [19] .
In support of the second mechanism, whereby HSV enhances HIV-1 transmission, in vitro studies have suggested that HSV can activate latent HIV-1 or enhance its replication [27] . In vivo studies demonstrating a direct correlation between HSV infection and increased HIV-1 burden have been rare. One small prospective study conducted among 16 patients demonstrated that an acute HSV episode can result in transient 3-4-fold increases in levels of plasma HIV-1 RNA [28] . In another study of 16 men with proven herpetic ulcers in Seattle, Schacker et al. [6] found large amounts of HIV-1 DNA in the ulcers, and treatment or healing of the ulcers was accompanied by a decrease in HIV-1 shedding. An important determinant of HIV-1 shedding may be the HIV-1 plasma load. We found a positive association, but of borderline significance, between HIV-1 RNA levels in plasma and in genital secretions. Studies conducted in industrialized countries have usually found a clearer association [29] . The difference could be partly explained by different sampling methods, which might have led to the presence of blood in the genital tract sample in other studies [29] , or could be attributed to the relatively small sample size and low power of our study. Alternatively, our data may support the notion of compartmentalization of HIV-1 replication, in keeping with previous studies demonstrating distinct viral HIV-1 variants, and immunological responses to HIV, between peripheral blood and the female genital tract [30] . Such data on women living in Africa are still scarce. It is possible that other systemic or local factors, in addition to HIV-1 plasma virus load, may be very important in determining genital shedding of HIV-1 in Africa, and these may include HSV-2 and other STDs, such as cervical infections or changes in the vaginal flora [31] , as was also observed in our study.
The interactions between HSV and HIV infections are not fully understood. Among HIV-positive individuals, HSV-2-associated GUD may enhance HIV shedding and infectiousness by disrupting genital mucosal integrity. Among HIV-negative individuals, HSV-2-associated GUD may increase susceptibility by disrupting mucosal integrity, but also by the recruitment and activation of HIV target cells, and possibly by HIV taking advantage of chemokine receptors [3] . A number of cohort studies have demonstrated that HSV-2 seroconversion, with or without obvious clinical disease, was a risk factor for HIV-1 seroconversion [3] . Studies to explain the mechanism by which the largely asymptomatic genital shedding of HSV-2 in women may act as a cofactor for HIV infection are lacking. Our crosssectional study cannot demonstrate a causal role of HSV-2 in HIV-1 transmission, and further longitudinal and intervention studies will be necessary to elucidate this point. However, in the face of the severe and worsening HIV-1 epidemic in Africa, the high prevalence of HIV-1 and HSV-2, and the high frequency of asymptomatic HSV-2 shedding, a possible synergistic effect between the infections, as suggested by this study, may be cause for concern. We have learned in the past decade that no single approach will contain the HIV/AIDS epidemic, and we need to consider all available means of control, however imperfect. The Mwanza study in Tanzania demonstrated that improved STD case management was an important additional HIV prevention strategy [32] , resulting in a 40% reduction in HIV incidence in the general population. No such reduction was achieved by STD mass treatment in the Rakai study in Uganda [13] , and one reason postulated for this was a higher prevalence in Rakai of STDs, such as genital herpes, that were not targeted by the antimicrobial regimen [33] .
Our data prompt a number of challenges and potential avenues for further research on genital herpes and STD/HIV control in Africa. To demonstrate the enhancing effect of HSV-2 on HIV transmission or acquisition, it will be necessary to conduct randomized intervention trials that specifically target HSV-2, measuring the outcome in terms of HIV shedding or HIV incidence, as well as HSV-2 shedding. Such interventions could include the addition of antiherpetic treatment to syndromic management algorithms for STD patients in Africa, which may become feasible now that acyclovir is out of patent; the provision of suppressive therapy against HSV-2 for individuals dually infected with HSV-2 and HIV, an option not likely to be feasible on a large scale in most developing countries, but which could be tried in high-risk groups, such as commercial sex workers; and the development and testing of preventive interventions, particularly those targeting youth [34] . However, it may be that the most realistic hope for control is the development of a safe and effective HSV-2 vaccine [34] .
